Cancer ResearchSkin Microbiome Shifts Detected in Immunotherapy Rash Patients
Immune checkpoint inhibitors — a major class of cancer immunotherapy drugs — cause skin rashes in up to 45% of treated patients. Researchers at City of Hope Medical Center investigated whether the bacterial communities living on affected skin differ from those on unaffected skin in the same patient. Using punch biopsies, they collected skin tissue to analyze microbial diversity and also compared immune cell profiles in skin versus blood. Understanding these microbial and immune differences could help explain why some patients develop dermatitis while others do not, and may point toward microbiome-based strategies to prevent or treat this common side effect. The study was small, enrolling only two participants, limiting the conclusions that can be drawn, but it represents early exploratory work in a clinically meaningful area.
